Abraxis backs SPARC as prognostic biomarker

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 6
Volume 18
Issue 6

SPARC (secreted protein acidic and rich in cysteine) may play a role in tumor growth and angiogenesis, according to preclinical data presented at AACR 2009.

SPARC (secreted protein acidic and rich in cysteine) may play a role in tumor growth and angiogenesis, according to preclinical data presented at AACR 2009.

Researchers at Abraxis BioScience, the manufacturer of Abraxane (nab-paclitaxel), found that recombinant human SPARC grown in vitro fostered angiogenesis and the development of mature blood vessels. SPARC may play a greater role in the angiogenic process beyond initiating the growth of new blood vessels, they said (abstracts 1478, 2572, 3769, 4017, 5168).

Articles in this issue
ADT in prostate ca increases risk of bone and heart complications
Abraxis backs SPARC as prognostic biomarker
ALK-1 receptor: New target in angiogenesis
Abraxane prolongs PFS in metastatic disease
SAVI applicator removes obstacles associated with brachytherapy
Mistrust, costs reduce breast cancer screening among minorities
Oral chemotherapy poses more challenges for cancer community
CMS nixes CT colonography screening
New ultrasound strategy helps pinpoint prostate tumors
New research on VEGF, gene mutations refines understanding of tumor angiogenesis
From the ONI archives: Should low-dose induction dexamethasone be standard of care in multiple myeloma?
Persistent circulating tumor cells predict worse outcomes in early breast cancer
Genomics takes center stage at AACR in chemoprevention and disease treatment
Gefitinib changes first-line Rx for lung ca in Asian pts
Who's News
Recent Videos
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Earlier and more frequent talks about disabling ICDs with patients receiving end-of-life care and their families may help avoid excessive pain.
3 experts in this video
3 experts in this video
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
Related Content
Developments in CAR T-Cell and Bispecific Therapies in R/R Multiple Myeloma

Developments in CAR T-Cell and Bispecific Therapies in R/R Multiple Myeloma

ONCOLOGY Staff
February 22nd 2025
Article

Hematology oncology experts discuss recent developments in CAR T-cell therapies as well as bispecific therapies for the treatment of patients with R/R MM.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Highlighting Insights From the Marginal Zone Lymphoma Workshop

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD
February 17th 2025
Podcast

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Tambiciclib/Zanubrutinib Yields Promising Responses in R/R DLBCL

Tambiciclib/Zanubrutinib Yields Promising Responses in R/R DLBCL

Tim Cortese
February 21st 2025
Article

Tambiciclib plus zanubrutinib doubled the expected ORR of zanubrutinib monotherapy, eliciting an ORR of 67% in patients with relapsed or refractory DLBCL.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Navigating Management and Dosing Considerations for Amivantamab in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
February 10th 2025
Podcast

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Understanding patient preferences for intensive end-of-life treatment may better inform research assessing patients with terminal cancer diagnoses.

Improving End-of-Life Care in ICD Users With Advanced Cancers

Megan Mullins, PhD, MPH
February 20th 2025
Article

Understanding patient preferences for intensive end-of-life treatment may better inform research assessing patients with terminal cancer diagnoses.

Results from the phase 1/2a SeCuRE trial support the FDA decision for patients with metastatic castration-resistant prostate cancer.

Cu-67 SAR-bisPSMA Granted Fast Track Designation for Metastatic CRPC

Roman Fabbricatore
February 20th 2025
Article

Results from the phase 1/2a SeCuRE trial support the FDA decision for patients with metastatic castration-resistant prostate cancer.